2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 408

Comorbidity In Early Rheumatoid Arthritis.Does Inflammation Matter ?
Abstract Number: 121

Comparative Burden Of Chronic Widespread Pain and Fibromyalgia In The US Population
Abstract Number: 2150

Comparative Effectiveness Of Pharmacological Interventions For Knee Osteoarthritis: A Network Meta-Analysis
Abstract Number: 1438

Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi
Abstract Number: 460

Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Abstract Number: 2030

Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 2801

Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Abstract Number: 149

Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Abstract Number: 2761

Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Abstract Number: 2319

Comparative Safety Of Biological Agents Among Medicare Rheumatoid Arthritis Patients
Abstract Number: 2306

Comparative Study Of Patients With Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis Without Psoriasis
Abstract Number: 1490

Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjögren’s Syndrome Patients Versus Healthy Controls Based On RNA-Seq
Abstract Number: 430

Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
Abstract Number: 335

Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Abstract Number: 363

Comparing Myocardial Infarction Risks Associated With Biologics Of Varying Mechanisms Of Action Among Older RA Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].